Publicaciones en colaboración con investigadores/as de Hospital Universitario San Cecilio (20)

2024

  1. Long or complicated mpox in patients with uncontrolled HIV infection

    Journal of Medical Virology, Vol. 96, Núm. 3

  2. The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers

    Journal of Clinical Investigation, Vol. 134, Núm. 8

2022

  1. DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)

    Viruses, Vol. 14, Núm. 3

  2. Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV

    Viruses, Vol. 14, Núm. 12

2020

  1. Genetic diversity of HIV in seminal plasma remains higher than in blood after short-term antiretroviral therapy

    Sexually Transmitted Infections, Vol. 96, Núm. 5, pp. 337-341

2017

  1. Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494

2016

  1. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens

    PLoS ONE, Vol. 11, Núm. 2

2015

  1. Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2247-2255

2014

  1. Clinical and virological efficacy of etravirine plus two active nucleos(t)ide analogs in an heterogeneous HIV-infected population

    PLoS ONE, Vol. 9, Núm. 5

2009

  1. Resistencias genotípicas en pacientes con VIH-1 y grados de viremia persistentemente bajos

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 27, Núm. 2, pp. 75-80

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

  2. Efficacy of pegylated interferon plus ribavirin treatment in HIV/ hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone

    Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 6, pp. 1365-1373

2005

  1. A case-control study of HIV patients with the K65R mutation in the reverse transcriptase gene with virological failure [2]

    AIDS

  2. Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: The VESD study

    HIV Clinical Trials, Vol. 6, Núm. 6, pp. 320-328

1998

  1. Comparative study of bacteremias caused by Enterococcus spp. with and without High-level resistance to gentamicin

    Journal of Clinical Microbiology, Vol. 36, Núm. 2, pp. 520-525

1997

  1. Imágenes nodulares hipodensas en bazo en un paciente con infección por el virus de la inmunodeficiencia humana

    Revista Clinica Espanola, Vol. 197, Núm. 7, pp. 529-530

  2. Meningitis por Streptococcus pneumoniae y Haemophilus influenzae en un adulto no inmunodeprimido [3]

    Enfermedades Infecciosas y Microbiologia Clinica

1996

  1. Frequency of Subclinical Visceral Leishmaniasis in HIV-1-Infected Patients in Spain

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 15, Núm. 3, pp. 263-264

1988

  1. Bone marrow aplasia in patient suffering A.I.D.S. treated with trimethoprim-Sulphamethoxazole

    Anales de Medicina Interna, Vol. 5, Núm. 3, pp. 141-145

  2. Hepatitis caused by carbamacepine

    Anales de Medicina Interna, Vol. 5, Núm. 12, pp. 644